Sistema de Salut de Catalunya
Institut Català de la Salut
[Channa R] Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin. [Wolf RM] Department of Pediatric Endocrinology, Johns Hopkins University School of Medicine, Baltimore, Maryland. [Simo R] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERDEM, Barcelona, Spain. [Brigell M] Consultant, Belmont, Massachusetts. [Fort P] Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan. [Curcio C] Department of Ophthalmology, University of Alabama, Birmingham, Alabama
Vall d'Hebron Barcelona Hospital Campus
2024-02-16T14:02:31Z
2024-02-16T14:02:31Z
2023-10-31
Biomarkers; Diabetic retinal disease; Neuro-retinal layers
Biomarcadores; Enfermedad de la retina diabética; Capas neurorretinianas
Biomarcadors; Malaltia de la retina diabètica; Capes neurorretinàries
Topic The goal of this review was to summarize the current level of evidence on biomarkers to quantify diabetic retinal neurodegeneration (DRN) and diabetic macular edema (DME). Clinical relevance With advances in retinal diagnostics, we have more data on patients with diabetes than ever before. However, the staging system for diabetic retinal disease is still based only on color fundus photographs and we do not have clear guidelines on how to incorporate data from the relatively newer modalities into clinical practice. Methods In this review, we use a Delphi process with experts to identify the most promising modalities to identify DRN and DME. These included microperimetry, full-field flash electroretinogram, spectral-domain OCT, adaptive optics, and OCT angiography. We then used a previously published method of determining the evidence level to complete detailed evidence grids for each modality. Results Our results showed that among the modalities evaluated, the level of evidence to quantify DRN and DME was highest for OCT (level 1) and lowest for adaptive optics (level 4). Conclusion For most of the modalities evaluated, prospective studies are needed to elucidate their role in the management and outcomes of diabetic retinal diseases.
Article
Published version
English
Marcadors bioquímics; Retinopatia diabètica; Edema; CHEMICALS AND DRUGS::Biological Factors::Biomarkers; DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Angiopathies::Diabetic Retinopathy; DISEASES::Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular Degeneration::Macular Edema; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores; ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::angiopatías diabéticas::retinopatía diabética; ENFERMEDADES::oftalmopatías::enfermedades de la retina::degeneración retiniana::degeneración macular::edema macular
Elsevier
Ophthalmology Science;4(3)
https://doi.org/10.1016/j.xops.2023.100420
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
